Penumbra Inc
No SEC Form 4 filings for $PEN in the last 30 days.
See all $PEN insider activity →Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.
Penumbra's CAVT technology received FDA clearance for treating deep-vein thrombosis (DVT). The BOLT-DVT trial showed 98% of patients had successful clot removal, with immediate pain relief and improved quality of life. No serious device-related adverse events were reported. Penumbra's Lightning Flash technology aims to enhance clot removal safety and efficiency.
Merit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PEN (Penumbra Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PEN coverage spans earnings, mergers & acquisitions and regulation.
Positive regulatory approval likely lifts Penumbra's near‑term share price.
Clearance unlocks a new market for Penumbra's DVT treatment, expanding revenue potential.
Strong revenue growth but EPS miss leads to neutral market reaction.
The announced acquisition creates upside potential for Penumbra shareholders at the deal price, but execution risk remains.
Accretive acquisition increasing production and reserves; potential upside from new country entry.
AlphAI scores every news story that mentions PEN with an AI model for sentiment and relevance, and aggregates insider trades from Penumbra Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.
1 min readPenumbra's CAVT technology received FDA clearance for treating deep-vein thrombosis (DVT). The BOLT-DVT trial showed 98% of patients had successful clot removal, with immediate pain relief and improved quality of life. No serious device-related adverse events were reported. Penumbra's Lightning Flash technology aims to enhance clot removal safety and efficiency.
2 min readMerit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.
2 min readBoston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).
2 min readPanoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.
2 min readPenumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of
4 min readPenumbra (NYSE: PEN) reported THUNDER IDE study results for its THUNDERBOLT computer-assisted vacuum thrombectomy system in emergent large vessel occlusion stroke. In 216 patients, 87.5% achieved mTICI 2b-3 reperfusion, with median time-to-revascularization of 20 minutes and 2.8% device/procedure-related serious adverse events. FDA clearance and CE Mark were noted.
4 min readPeninsula Energy Limited (ASX:PEN) shares fell about 26.03% intraday on 22 July 2026, according to a market snapshot. The company operates the Lance ISR uranium project in Wyoming and reaffirmed 2026 guidance of 400,000 to 500,000 lb U3O8 and 2027 guidance of 500,000 to 600,000 lb. In May 2026 it secured about US$56m funding. No specific disclosure was identified for the exact move.
7 min readPenumbra said the FDA cleared its Thunderbolt computer-assisted vacuum thrombectomy device for acute ischemic stroke, aimed at distal occlusions. Thunderbolt uses modulated aspiration with standard aspiration to help remove clots more completely. IDE study results will be presented in July, and Penumbra also reported a CE Mark and starting the Forward study.
4 min readPennant International Group plc (AIM: PEN) said it has made its first sale of Auxilium–GenS via its Siemens partnership to a North American digital engineering customer supporting defence, national security and space missions. The sale follows a July 2025 agreement under which Siemens Digital Industries Software is licensed to distribute Auxilium–GenS through its Teamcenter platform.
4 min read
